Search

FB-101

Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102] … FB-101 is a c-Abl inhibitor.

PS386113

PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

BHV-5000

BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

OTL-201

OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973]

Tilmanocept

Tilmanocept is under investigation in clinical trial NCT03241446 (Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed

Iodamide

Iodamide is a contrast medium molecule that is no longer marketed in the United States.

Puromycin

Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. … Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.

Vercirnon

Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. … It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).

Debamestrocel

Debamestrocel is under clinical development by BrainStorm Cell Therapeutics and is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47266]

Sodium metavanadate